SFA Therapeutics, Inc. Press Releases

• Published on October 17, 2022 - 12:00 GMT

  

  Dr. Daniel Sauder joins the SFA Therapeutics Scientific Advisory Board

  An experienced Key Opinion Leader in Dermatology, Dr. Sauder will add significant input to the dermatology development program at SFA Therapeutics JENKINTOWN, PA, UNITED STATES, October 17, 2022 /⁨EINPresswire.com⁩/ -- SFA Therapeutics is pleased to …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on September 23, 2022 - 12:00 GMT

  

  SFA Therapeutics Publishes Research on its New Approach to Treating Hepatitis B and Chronic Liver Disease

  A new approach to treating Hepatitis B and Chronic Liver Disease, with the the goal of developing a functional cure JENKINTOWN, PA, UNITED STATES, September 23, 2022 /⁨EINPresswire.com⁩/ -- SFA Therapeutics, Inc. is pleased to announce a new publication …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on June 20, 2022 - 12:00 GMT

  

  SFA THERAPEUTICS, INC. CLOSES SEED ROUND RAISE of $4M

  Funds are focused on Phase 1b clinical trial in psoriasis JENKINTOWN, PA, UNITED STATES, June 20, 2022 /⁨EINPresswire.com⁩/ -- SFA Therapeutics, Inc. is pleased to announce that our Seed funding round has closed. Our original seed raise of $2 million was …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on December 30, 2021 - 12:30 GMT

  

  Mr. Rob Dickey joins SFA Therapeutics as Chief Financial Officer and Board member

  SFA Therapeutics is pleased to announce that Mr. Rob Dickey IV has joined us as our Chief Financial Officer and as a Board member. JENKINTOWN, PA, UNITED STATES, December 30, 2021 /⁨EINPresswire.com⁩/ -- SFA Therapeutics is pleased to announce that Mr. …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on December 30, 2021 - 12:00 GMT

  

  Mr. Shawn Patrick O’Brien joins SFA Therapeutics as a Strategic Advisor and Chairman

  Shawn O’Brien joins SFA Therapeutics as a Strategic Advisor and Chairman JENKINTOWN, PA, UNITED STATES, December 30, 2021 /⁨EINPresswire.com⁩/ -- SFA Therapeutics is pleased to announce that Shawn Patrick O’Brien has joined our Board as a Strategic …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on October 15, 2021 - 11:00 GMT

  

  SFA Therapeutics Ranked Most Fundable Company by Pepperdine Graziadio Business School

  LOS ANGELES, CA, UNITED STATES, October 15, 2021 /⁨EINPresswire.com⁩/ -- SFA Therapeutics is pleased to announce that it achieved a Gold recognition on the Pepperdine Graziadio Business School’s fourth annual Most Fundable Companies® List. SFA Therapeutics …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on May 24, 2021 - 12:00 GMT

  

  SFA Therapeutics Selected as 2021 Company and Pitch Presentation Award Honoree at 11th Annual BioPartnering Conference

  Award Honoree in Therapeutics & Enabling Technologies JENKINTOWN, PA, UNITED STATES, May 24, 2021 /⁨EINPresswire.com⁩/ -- BioNJ announced the winners of its 2021 Company and Pitch Presentation Competition held in conjunction with the organization' …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on April 8, 2021 - 10:00 GMT

  

  SFA THERAPEUTICS, INC. ANNOUNCES START OF PHASE 1b CLINICAL TRIAL IN THE TREATMENT OF MILD-to-MODERATE PLAQUE PSORIASIS

  SFA002 is a new oral therapeutic agent for the treatment of mild-moderate psoriasis; which is also being targeted for other autoimmune diseases JENKINTOWN, PA, UNITED STATES, April 8, 2021 /⁨EINPresswire.com⁩/ -- SFA Therapeutics, Inc., a clinical-stage …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...